The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Hitomi SezakiFumitaka SuzukiTetsuya HosakaNorio AkutaShunichiro FujiyamaYusuke KawamuraMasahiro KobayashiYoshiyuki SuzukiSatoshi SaitohYasuji AraseKenji IkedaMariko KobayashiHiromitsu KumadaPublished in: Liver international : official journal of the International Association for the Study of the Liver (2017)
Dual oral therapy with DCV and ASV in real-life settings was well tolerated with a similar safety profile and achieved similar SVR12 rates as that of CTR.
Keyphrases